Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CC-91633 |
Synonyms | |
Therapy Description |
CC-91633 (BMS-986397) degrades and inhibits the activity of casein kinase 1 alpha, resulting in impaired interaction of MDM2 with p53 and thereby leading to elevated p53 activity, potentially resulting in cell cycle arrest and decreased tumor cell proliferation (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CC-91633 | CC 91633|CC91633|BMS-986397|BMS986397|BMS 986397 | CC-91633 (BMS-986397) degrades and inhibits the activity of casein kinase 1 alpha, resulting in impaired interaction of MDM2 with p53 and thereby leading to elevated p53 activity, potentially resulting in cell cycle arrest and decreased tumor cell proliferation (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04951778 | Phase I | CC-91633 | Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes | Recruiting | USA | GBR | ESP | CAN | AUS | 0 |